Pituitary macroadenoma: a case report and review

Herse, Peter

doi:10.1111/cxo.12099

Cited by 14 publications

(11 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Four to six millimetres of chiasmal elevation is needed to produce visual field defects. A more detailed study found that 6.3 mm of chiasmal elevation was required to induce visual field defects in 50 per cent of patients and an additional 5.0 mm is needed to increase the frequency to 90 per cent [5]. In this case, although the MRI showed the pituitary tumour impinges on the optic chiasma, but patient did not show any visual defects.…”

Section: Discussionmentioning

confidence: 70%

Light up the Future – a New Paradigm: Photobiomodulation as a Non-Surgical Cancer Treatment Modality: a Case Report

2019

JSCR

View full text Add to dashboard Cite

Non Functioning Pituitary Macroadenoma (NFPA) comprise about 80% of all pituitary macroadenomas. NFPAs are frequently found incidentally during imaging studies performed for unrelated reasons.Photobiomodulation (PBM) is a non-evasive technique that uses certain wavelengths of light to restore, repair, and protect tissue that is either injured, degenerating, or at risk of dying. It has the ability to promote the body’s own immune responses and are able to penetrate into the cells, tissues, blood, nerves, the brain, and into the bones. Perhaps besides radical surgical approach, we could explore adjuvant methods of treatments to complement this. In conclusion, PBM might be introduced as an adjunct treatment option for patients with brain tumour, non-operable brain lesions or those who declined radical surgery and opted for active surveillance.This case report highlightsphotobiomodulation antitumourigenesis effects in reduction of pituitary tumour volume.

show abstract

Section: Discussionmentioning

confidence: 70%

Light up the Future – a New Paradigm: Photobiomodulation as a Non-Surgical Cancer Treatment Modality: a Case Report

2019

JSCR

View full text Add to dashboard Cite

show abstract

“…[147][148][149] Chiasmal defects are characteristically bitemporal (Figure 8), with a bias toward either superior (for example, pituitary adenoma) or inferior (for example, craniopharyngioma) bitemporal defects, depending on aetiology. 146,150 Visual field losses in the far superotemporal and inferotemporal regions of the field may at first be subtle and the wider and symmetrical 30-2 test grid may be required.…”

Section: Beyond the Retina And Optic Nervementioning

confidence: 99%

The value of visual field testing in the era of advanced imaging: clinical and psychophysical perspectives

Phu

Khuu

Yapp

et al. 2017

Clinical and Experimental Optometry

View full text Add to dashboard Cite

White‐on‐white standard automated perimetry (SAP) is widely used in clinical and research settings for assessment of contrast sensitivity using incremental light stimuli across the visual field. It is one of the main functional measures of the effect of disease upon the visual system. SAP has evolved over the last 40 years to become an indispensable tool for comprehensive assessment of visual function. In modern clinical practice, a range of objective measurements of ocular structure, such as optical coherence tomography, have also become invaluable additions to the arsenal of the ophthalmic examination. Although structure‐function correlation is a highly desirable determinant of an unambiguous clinical picture for a patient, in practice, clinicians are often faced with discordance of structural and functional results, which presents them with a challenge. The construction principles behind the development of SAP are used to discuss the interpretation of visual fields, as well as the problem of structure‐function discordance. Through illustrative clinical examples, we provide useful insights to assist clinicians in combining a range of clinical results obtained from SAP and from advanced imaging techniques into a coherent picture that can help direct clinical management.

show abstract

“…Pa cien tai ga li il gai nepa ste bë ti po ky èiø ir jaus tis ge rai [13]. Daþ niau siai skundþia ma si gal vos skaus mais (23-48 %) ir re gos su tri ki mais (37-100 %), la bai re tai aug lys pa si reið kia trau ku liais, ri norë ja ar hi po fi zës apo plek si ja [10,44]. Gal vos skaus mà, kuris ne pri klau so nuo na vi ko dy dþio, su ke lia kie tø jø dan ga lø tem pi mas [45].…”

Section: Klinika Ir Diagnostikaunclassified

“…Re gos su tri ki mai, prie ðin gai, pri klau so nuo na vi ko dy dþio ir au gi mo kryp ties -HA ga li spaus ti re gos ner vø kryþ mae, gal vi nius ner vus (akies ju di na mà já, skri dini ná, ati trau kia mà já) [10,44]. Daþ niau si re gos simp to mai: bi tem po ra li në he mia nop si ja (54-69 %), ki ti aki plo èio sutri ki mai (85 %), su ma þë jaes re gos aðt ru mas (42-88 %) [10,44,46].…”

Section: Klinika Ir Diagnostikaunclassified

“…La bai svar bu yra of tal mo lo go kon sul ta ci ja ir re gos funk ci jos ið ty ri mas, net ir ne pa si reið kus jos su tri ki mams, nes pa leng va pro gresuo jan èiø simp to mø (pvz., bi tem po ra li nës he mia nop si jos) pa cien tas ga li ne pa ste bë ti [10,46]. Re ko men duo ja ma atlik ti ir op ti nae ko he ren ti nae to mog ra fi jà, nes, jei HA spaudþia re gos ner vo kryþ mae, dël ak so nø de ge ne ra ci jos plo në ja re gos ner vo dis ko skai du los [44].…”

Section: Klinika Ir Diagnostikaunclassified

See 1 more Smart Citation

Pituitary adenoma: a literature review

Sidaraitė

Glebauskiene

Liutkevičienė

2018

View full text Add to dashboard Cite

ÁVADASHi po fi zës ade no mø (HA) pa pli ti mas po pu lia ci jo je yra 1:1000, taip pat jos su da ro 15-20 % vi sø in trak ra ni ji niø na vi kø [1][2][3]. Diag no zë nu sta to ma ávai raus am þiaus as menims (16-79 m.), vi du ti nið kai 37 m. pa cien tams [4]. Pa gal dy dá HA yra skirs to mos á mik ro ade no mas (ma þiau nei 1 cm dia met ro), mak ro a de no mas (1 cm ir di des nio dia metro) ir la bai di de les ade no mas (dau giau nei 4 cm dy dþio) [5]. Daþ niau sios yra mik ro ade no mos, su da ran èios 50-60 % at ve jø [6]. Nors HA yra lai ko mos ge ry bi niais aug liais, vis dau giau moks li nin kø ma no, kad to kia sam prata tu ri kis ti: 30-45 % jø yra lin ku sios plis ti á aky tuo sius ar pleið ta kau lio an èius, yra at spa rios gy dy mui ir lin ku sios atsi nau jin ti [5]. Be vie ti nio spau di mo su kel tø reið ki niø, HA ga li su kel ti ir en dok ri no lo gi nius su tri ki mus, tai gi kli ni ka tam pa la bai ávai ri ir sun ki na sa va lai kae diag nos ti kà, ku ri yra ypaè svar bi ag re sy viø HA at ve ju. Ak ty viai ieð ko ma spe cifi niø bio mar ke riø, ta èiau në vie nas në ra uþ tek ti nai spe cifið kas ðiam na vi kui. Tam áta kos ga li tu rë ti dar ne vi sið kai ið si aið kin ta HA pa to ge ne zë [7,8]. KLASIFIKACIJAPa gal Pa sau lio Svei ka tos Or ga ni za ci jà (PSO), hi po fi zës na vi kai yra skirs to mi á ti pi nes ade no mas, ne ti pi nes ade nomas ir kar ci no mas. Ti pi nës ade no mos, dar ben drai va di namos hi po fi zës ade no mo mis, yra daþ niau sios ið ðios gru pës, jos au ga lë tai, daþ nai tu ri aið kias ri bas ir yra ma þo in va zyvu mo, prie ðin gai nei ati pi nës ade no mos. Hi po fi zës kar cino mos yra re tos, jos ga li at si ras ti de novo ar ba bû ti pas ku tine ade no mø pro gre sa vi mo sta di ja, taip pat jos lin ku sios me ta sta zuo ti tiek cen tri në je ner vø sis te mo je (CNS), tiek ir ki tuo se or ga nuo se [8].HA is to rið kai bu vo kla si fi kuo ja mos pa gal da þy mà si eozi no-he ma tok si li no da þais á aci do fi li nes, ba zo fi li nes ir chro mo fo bi nes ade no mas [8,9]. Da bar yra re mia ma si làs -te lës ti pu, ið ku rios ki lo aug lys, ir ade no mos hor mo ni niu ak ty vu mu. Jei tam tik rø hor mo nø kon cen tra ci jos pa di dë ji -14 NEUROLOGIJOS SEMINARAI • ISSN 1392-3064 / eISSN 2424-5917 © Neurologijos seminarai, 2018. Open Ac cess. This ar ti cle is dis trib uted un der the terms of the Cre ative Com mons At tri bu tion 4.0 Inter na tional Li cense CC-BY 4.0 (http://creativecommons.org/licenses/by/4.0/), which per mits un re stricted use, dis tri bu tion, and re produc tion in any me dium, pro vided you give ap pro pri ate credit to the orig i nal au thor(s) and the source, pro vide a link to the Cre ative Com mons li cense, and in di cate if changes were made. San trau ka. Hi po fi zës ade no ma (HA) yra vie nas daþ niau siø in trak ra ni ji niø na vi kø, ga lin tis su kel ti neu ro lo gi nius ir (ar) en dok ri no lo gi nius simp to mus. Vis gi, pa to ge ne zë dar në ra iki galo aið ki, ðei mi niai at ve jai ir su jais su si jae sin dro mai yra ...

show abstract

Pituitary macroadenoma: a case report and review

Cited by 14 publications

References 70 publications

Light up the Future – a New Paradigm: Photobiomodulation as a Non-Surgical Cancer Treatment Modality: a Case Report

Light up the Future – a New Paradigm: Photobiomodulation as a Non-Surgical Cancer Treatment Modality: a Case Report

The value of visual field testing in the era of advanced imaging: clinical and psychophysical perspectives

Pituitary adenoma: a literature review

Contact Info

Product

Resources

About